» Articles » PMID: 33073396

Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System

Abstract

Background And Aims: Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread.

Approach And Results: Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCC v.7) data were eligible. Modified staging was used (mAJCC v.7): group A: stages I-III (excluding T2bN0); group B: stage IVa (excluding T2bN1M0); group C: liver metastases (T2bN0/1); and group D: stage IVb (extrahepatic metastases). Survival analysis (Kaplan-Meier and Cox regression) was performed in an ENS-CCA training cohort (TC) and findings internally (ENS-CCA iVC) and externally (SEER) validated. The aim was to assess whether liver metastases (group C) had a shorter survival compared to other early stages (group A) to propose a modified version of AJCC v.8 (mAJCC v.8). A total of 574 and 4,171 patients from the ENS-CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS-CCA and SEER registries were reclassified into group C, respectively. In the ENS-CCA TC, multivariable Cox regression was adjusted for obesity (p = 0.026) and performance status (P < 0.001); patients in group C (HR, 2.53; 95% CI, 1.18-5.42; P = 0.017) had a higher risk of death (vs. group A). Findings were validated in the ENS-CCA iVC (HR, 2.93; 95% CI, 2.04-4.19; P < 0.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68-2.09; P < 0.001).

Conclusions: iCCA with liver metastases has a worse outcome than other early stages of iCCA. Given that AJCC v.8 does not take this into consideration, a modification of AJCC v.8 (mAJCC v.8), including "liver metastases: multiple liver lesions, with or without vascular invasion" as an "M1a stage," is suggested.

Citing Articles

The comprehensive potential of AQP1 as a tumor biomarker: evidence from kidney neoplasm cohorts, cell experiments and pan-cancer analysis.

Liu Y, Lyu D, Yao Y, Cui J, Liu J, Bai Z Hum Genomics. 2025; 19(1):15.

PMID: 39988693 PMC: 11849320. DOI: 10.1186/s40246-025-00726-9.


Standardizing the reporting of cholangiocarcinoma: the society of abdominal radiology disease focused panel on cholangiocarinoma lexicon.

Marks R, Arif H, Antonietta Bali M, Brunsing R, M Cunha G, Khasawneh H Abdom Radiol (NY). 2025; .

PMID: 39775025 DOI: 10.1007/s00261-024-04769-9.


Long-Term Survivor of Intrahepatic Cholangiocarcinoma for over 18 Years: Case Study with Longitudinal Histo-molecular and Tumor Immune Microenvironment Characterization and Systematic Review of the Literature.

Mattiolo P, De Bellis M, Mafficini A, Fassan M, Bevere M, Ciulla C J Gastrointest Cancer. 2024; 55(4):1634-1646.

PMID: 39283582 PMC: 11464565. DOI: 10.1007/s12029-024-01113-8.


Epigenetic silencing of miR-125a-3p promotes the progress of human cholangiocarcinoma via increasing CAC1 expression.

Guo X, Wang J, Tian Y, Yang J, Wu S, Xin L Heliyon. 2024; 10(12):e32528.

PMID: 38994075 PMC: 11237926. DOI: 10.1016/j.heliyon.2024.e32528.


The Clinical Association Between the Inflammation-Nutritional Condition and Prognosis of Locally Advanced Intrahepatic Cholangiocarcinoma After R0 Resection: Evidence from Competing Risk and Propensity Matching Analysis.

Huang G, Xi P, Yao Z, Zhao C, Li X, Chen Z J Inflamm Res. 2024; 17:2787-2799.

PMID: 38737115 PMC: 11088411. DOI: 10.2147/JIR.S460103.


References
1.
Spolverato G, Bagante F, Weiss M, Alexandrescu S, Marques H, Aldrighetti L . Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017; 115(6):696-703. DOI: 10.1002/jso.24569. View

2.
Patel T . Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33(6):1353-7. DOI: 10.1053/jhep.2001.25087. View

3.
Lamarca A, Edeline J, McNamara M, Hubner R, Nagino M, Bridgewater J . Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020; 84:101936. DOI: 10.1016/j.ctrv.2019.101936. View

4.
Al-Adra D, Gill R, Axford S, Shi X, Kneteman N, Liau S . Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2014; 41(1):120-7. PMC: 4316196. DOI: 10.1016/j.ejso.2014.09.007. View

5.
Ronnekleiv-Kelly S, Pawlik T . Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017; 6(1):35-43. PMC: 5332207. DOI: 10.21037/hbsn.2016.10.02. View